340B Drug Pricing Program
The 340B drug savings program must be reformed, Health and Human Services Secretary Alex Azar said today at a 340B conference in Washington, D.C.
The House Energy and Commerce Health Subcommittee today posted more than a dozen bills and discussion drafts related to the 340 drug savings program as it prepares to hold a July 11 hearing on improving the program.
In a report issued today, the Government Accountability Office recommended that the Health Resources and Services Administration take additional steps to ensure contract pharmacies comply with 340B drug savings program requirements.
The information below supplements the March 29, 2018 memorandum AHA’s outside counsel prepared regarding 340B claims submission during the legal challenge to the 2018 outpatient prospective payment system rule reducing reimbursements for 340B claims beginning Jan. 1, 2018.
The Senate Health, Education, Labor and Pensions Committee today held the third in a series of hearings examining the 340B drug savings program.
At the hearing, Capt. Krista Pedley, director of the Office of Pharmacy Affairs at the Health Resources and Services Administration, which oversees…
AHA Statement before the Senate Committee on Health, Education, Labor and Pensions regarding “Effective Administration of the 340B Drug Pricing Program.”
June 14, 2018 - Appellants provide two recent notices issue by Medicare Administrative Contractors (MACs). The notices confirm that the rulemaking process was Appellants' only administrative opportunity to present their challenge to the rule at issue in this case and that Appellants will not be…
On behalf of our nearly 5,000 member hospitals, health systems and other health care organizations, and our clinician partners – including more than 270,000 affiliated physicians, 2 million nurses and other caregivers – and the 43,000 health care leaders who belong to our professional membership…
Rep. Doris Matsui (D-CA) today introduced an AHA-supported bill that would make changes to the 340B drug savings program, including overturning last year’s significant Medicare payment reduction for many hospitals in the program and adding program integrity requirements for drug manufacturers…
The Department of Health and Human Services today delayed until July 1, 2019 implementation of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers.